Janssen Search
Search results
TREMFYA® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
Mar 03, 2023 United States Studies suggest mechanistic benefit of guselkumab by binding to cells that drive inflammation in the colon SPRING HOUSE, PENNSYLVANIA, March 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today ...
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX®
Jun 04, 2024 If approved, PREZCOBIX® would offer a new HIV-1 treatment option for pediatric patients aged 6 and older weighing at least 25 kg Titusville, N.J. (June 4, 2024) – Johnson & Johnson today announced the submission of a supplemental New Drug ...
Janssen Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy EDURANT®
Jul 28, 2023 United States Parallel application also submitted to European Medicines Agency If approved, EDURANT ® (rilpivirine) in combination with other antiretroviral therapies would offer a new HIV-1 treatment option for younger children TITUSVILLE, N ...
Our Commitment to Rheumatology
Our Commitment to Rheumatology Jul 03, 2023 Subhead: Lorem ipsum dolor sit amet, consectetuer adipiscing elit About Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic, symmetric, inflammatory disease involving the synovial joints, where bone and ...
Late-Breaking Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Hemodynamics versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)
Mar 06, 2023 United States Study findings presented during the American College of Cardiology’s 72nd Annual Scientific Session & Expo Together With World Heart Federation’s World Congress of Cardiology European Society of Cardiology/European ...
Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24
Apr 04, 2024 United States Clinical and real-world evidence presentations highlight how the Company is transforming care for patients who are fighting some of the most common and devastating cardiovascular diseases NEW BRUNSWICK, NJ (April 4, 2024) – ...